Tracers / [68Ga]Ga-DOTA-D-Phe-Tyr3-octreotide

[68Ga]Ga-DOTA-D-Phe-Tyr3-octreotide

Also written as DOTA-D-Phe-Tyr3-octreotide; Ga-68 DOTA-D-Phe-Tyr3-octreotide; Ga-68-DOTA-D-Phe-Tyr3-octreotide

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: approved/clinical use
Syntheses indexed: 3

Neuroendocrine neoplasms

What it is

Compound class: radiolabeled somatostatin analog
Target / mechanism: Somatostatin receptor (SSTR) PMID 42606001
Clinical application: Neuroendocrine tumors/neoplasms PMID 42526976
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	—	—	—	24382404 2015 Q J Nucl Med Mol Imaging
—	—	—	—	—	—	15872348 2005 J Nucl Med
—	—	—	—	—	—	14499161 2003 Mol Imaging Biol

Need this precursor?We can point you to suppliers for [68Ga]Ga-DOTA-D-Phe-Tyr3-octreotide, or handle the enquiry for you.

Get in touch

Quality control Preliminary — inferred from compound class

Ph. Eur. monograph: —
USP monograph: —

AppearancepHRCP HPLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activityMetal impuritiesGe-68 breakthrough

How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); radiometal tracer -> metal impurities (rule); Ga-68, generator production assumed (no synthesis data found) -> Ge-68 breakthrough (preliminary); receptor ligand with a saturable target -> molar activity (rule)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [68Ga]Ga-DOTA-D-Phe-Tyr3-octreotide.

Get in touch

Notes

Added from reverse module search (stage 6); 2 article(s) with Ga-68.